{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:02:33Z","timestamp":1789614153575,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.breast.2026.104896","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:28:35Z","timestamp":1787095715000},"page":"104896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Revisiting HER2-negative breast cancer in the era of HER2-low and HER2-ultralow expression: Assessment of interobserver variability"],"prefix":"10.1016","volume":"89","author":[{"given":"Xiao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Dal Zotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuko","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea G","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1255-0283","authenticated-orcid":false,"given":"Meiling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4417-593X","authenticated-orcid":false,"given":"Shi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104896_bib1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41571-023-00849-9","article-title":"Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives","volume":"21","author":"Marra","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.breast.2026.104896_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104896_bib3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American society of clinical oncology\/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104896_bib4","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104896_bib5","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104896_bib6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.5858\/arpa.2023-0950-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer","volume":"147","author":"Wolff","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.breast.2026.104896_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.7239","article-title":"Examination of low ERBB2 protein expression in breast cancer tissue","volume":"8","author":"Fernandez","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104896_bib8","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-Low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104896_bib9","first-page":"645","volume":"vol. 34","author":"Tarantino","year":"2023"},{"key":"10.1016\/j.breast.2026.104896_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231152842","article-title":"The HER2-low revolution in breast oncology: steps forward and emerging challenges","volume":"15","author":"Nicol\u00f2","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.breast.2026.104896_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104896_bib12","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104896_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100009","article-title":"Interobserver variation in the assessment of immunohistochemistry expression levels in HER2-Negative breast cancer: can we improve the identification of low levels of HER2 expression by adjusting the criteria? An international interobserver study","volume":"36","author":"Baez-Navarro","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.breast.2026.104896_bib14","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ajcp\/aqac184","article-title":"Interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-Low-Expressing breast cancer cohort","volume":"159","author":"Karakas","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.breast.2026.104896_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ breast cancer"},{"key":"10.1016\/j.breast.2026.104896_bib16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10549-024-07256-3","article-title":"Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis","volume":"205","author":"Sun","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104896_bib17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.breast.2023.06.005","article-title":"Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the Republic of Ireland -on behalf of the UK national coordinating committee for breast pathology","volume":"70","author":"Zaakouk","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104896_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104127","article-title":"Interobserver consistency and diagnostic challenges in HER2-ultralow breast cancer: a multicenter study","volume":"10","author":"Wu","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104896_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13058-025-02001-0","article-title":"Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China","volume":"27","author":"Lv","year":"2025","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2026.104896_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105860","article-title":"Comparative study of intra- and inter-observer variability in manual scoring of HER2 immunohistochemical stains on glass slides versus paired digital images with emphasis on the low end of the expression spectrum","volume":"161","author":"Xiao","year":"2025","journal-title":"Hum Pathol"},{"key":"10.1016\/j.breast.2026.104896_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100032","article-title":"Multi-institutional assessment of pathologist scoring HER2 immunohistochemistry","volume":"36","author":"Robbins","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.breast.2026.104896_bib22","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.clbc.2021.05.004","article-title":"Discordance between immunohistochemistry and in situ hybridization to detect HER2 overexpression\/gene amplification in breast cancer in the Modern Age: a single institution experience and pooled literature review study","volume":"22","author":"Memon","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2026.104896_bib23","series-title":"Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast","author":"Allison","year":"2025"},{"key":"10.1016\/j.breast.2026.104896_bib24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/his.15275","article-title":"Best practices for achieving consensus in HER2-low expression in breast cancer: current perspectives from practising pathologists","volume":"85","author":"Tozbikian","year":"2024","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.breast.2026.104896_bib25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1037\/h0031619","article-title":"Measuring nominal scale agreement among many raters","volume":"76","author":"Fleiss","year":"1971","journal-title":"Psychol Bull"},{"key":"10.1016\/j.breast.2026.104896_bib26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med"},{"key":"10.1016\/j.breast.2026.104896_bib27","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","article-title":"Intraclass correlations: uses in assessing rater reliability","volume":"86","author":"Shrout","year":"1979","journal-title":"Psychol Bull"},{"key":"10.1016\/j.breast.2026.104896_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100783","article-title":"Incidence, clinicopathologic features, and Follow-Up results of human epidermal growth factor receptor-2-Ultralow breast carcinoma","volume":"38","author":"Hu","year":"2025","journal-title":"Mod Pathol"},{"key":"10.1016\/j.breast.2026.104896_bib29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13000-024-01557-3","article-title":"Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer","volume":"19","author":"Guan","year":"2024","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.breast.2026.104896_bib30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10549-023-07079-8","article-title":"Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients","volume":"202","author":"Chen","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104896_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100901","article-title":"Human epidermal growth factor receptor 2 (HER2)-ultralow breast cancer: incidence, clinicopathologic features, and need for refined scoring system","volume":"38","author":"Morrar","year":"2025","journal-title":"Mod Pathol"},{"key":"10.1016\/j.breast.2026.104896_bib32","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41379-022-01019-5","article-title":"HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles","volume":"35","author":"Zhang","year":"2022","journal-title":"Mod Pathol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:28:20Z","timestamp":1789612100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626002067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"alternative-id":["S0960977626002067"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104896","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting HER2-negative breast cancer in the era of HER2-low and HER2-ultralow expression: Assessment of interobserver variability","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104896","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104896"}}